Navigation Links
BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimer's Disease
Date:5/12/2010

diana's outstanding research community," continued Johnson. 

AgeneBio's first therapy is targeted at a very early form of AD called Amnestic Mild Cognitive Impairment (aMCI), a neurological condition that often progresses to Alzheimer's disease and affects more than 3 million aging Americans.  A proof of concept study is underway evaluating AgeneBio's lead therapy in patients with this condition, and its early platform technologies are being explored for a number of neurological conditions. 

"The investment by BioCrossroads will help us advance our research and formulations work so we can accelerate the development of our therapeutic program," said Tim Parshall, CEO of AgeneBio.  "We've been working closely with investors and consultants in Indiana and have been using a global sourcing network to bring our first product to phase II trials.  Indiana's positive entrepreneurial and scientific environment for life sciences companies was a significant factor in our decision to establish our company here."

If  there is a positive outcome from the clinical study, AgeneBio will seek the use of an accelerated approval pathway from the U.S. Food and Drug Administration (FDA)  to bring its first product to market, potentially shortening the normal pharmaceutical development timeline by as much as five years.    

According to DataMonitor,  aMCI-specific annual sales are expected to increase seven-fold from 2007 to $3.3 billion by 2018.   

About BioCrossroads

BioCrossroads (

SOURCE BioCrossroads
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services
2. BioCrossroads Indiana Seed Fund Invests in Vaccine Biotech Company
3. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
4. The PLSG Invests $115,000 in Innovention Technologies, LLC
5. The Pittsburgh Life Sciences Greenhouse Invests $100,000 in ParentPlus
6. Roche Molecular Diagnostics Invests $57.5 Million in Green Research Building
7. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
8. JIC Invests in Three New Alternative Energy Projects
9. JumpStart Invests in Tursiop Technologies
10. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences
11. Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Colo. , Jan. 23, 2015  Array BioPharma Inc. ... has reached a definitive agreement with Novartis Pharma AG ... inhibitor currently in Phase 3 development.  This agreement is conditional ... GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected ...
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), ... to the pharmaceutical and biotech industry, has announced that ... the position of Director of Science & Technology. , ... experience in drug metabolism and bioanalysis to EZVS in ...
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... April 5, 2012  Albright Stonebridge Group (ASG), a ... four new senior advisors – Hakan Akbas, Steven ... focus on leading ASG,s commercial activities and advising ... will support clients of ASG,s Brazil practice as ...
... 2012 BIND Biosciences, a clinical-stage biopharmaceutical company developing ... therapeutics called AccurinsTM, that are capable of up to ... has published preclinical and clinical data in Science ... and successful clinical translation of BIND-014, the first targeted ...
... (March X, 2012) framergyTM, which was recently accepted ... up with engineers from the Space Alliance Technology Outreach ... initiative designed to speed the transfer of knowledge and ... to propel commercialization of its proprietary energy-storing Metal Organic ...
Cached Biology Technology:Experts Strengthen Albright Stonebridge Group's Global Reach 2Experts Strengthen Albright Stonebridge Group's Global Reach 3First targeted and programmable nanomedicine to show clinical antitumor effects published 2First targeted and programmable nanomedicine to show clinical antitumor effects published 3First targeted and programmable nanomedicine to show clinical antitumor effects published 4framergyTM to partner with the Space Alliance Technology Outreach Program 2framergyTM to partner with the Space Alliance Technology Outreach Program 3
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Alberta researchers have developed a new web-based tool to ... for injured workers, helping them feel better and get ... of artificial intelligence called machine learning to analyze injury ... create a tool that recommends an appropriate course of ...
... Jeff Gore, Ph.D. , an assistant professor in physics at Massachusetts Institute ... Gore is studying how game theory can be applied to bacterial evolution, ... ... Inspired by Richard Dawkin,s The Selfish Gene, Gore is interested in the ...
... a simple "ouch" to the chronic and excruciating, has been ... a promising step toward studying pain in action. In a ... Society , scientists describe the development of a new technique, ... ways to relieve pain and monitor healing. Sandip Biswal, ...
Cached Biology News:Online tool aids clinicians' efforts to treat injured workers 2
CHIMAERIC HUMAN IgA2 ANTI NP...
ANTI NO-TRYPTOPHAN CONJUGATE...
... The Captivate magnetic ... can be used in conjunction ... (C-21473, C-21474, C-21476) or other ... with most 96-well microplates. Cell ...
Protein Phosphorylation...
Biology Products: